Promise and pitfalls of quantitative imaging in oncology clinical trials

Brenda F. Kurland, Elizabeth R. Gerstner, James M. Mountz, Lawrence H. Schwartz, Christopher Ryan, Michael M. Graham, John M. Buatti, Fiona M. Fennessy, Edward A. Eikman, Virendra Kumar, Kenneth M. Forster, Richard L. Wahl, Frank S. Lieberman

    Research output: Contribution to journalArticle

    45 Citations (Scopus)

    Abstract

    Quantitative imaging using computed tomography, magnetic resonance imaging and positron emission tomography modalities will play an increasingly important role in the design of oncology trials addressing molecularly targeted, personalized therapies. The advent of molecularly targeted therapies, exemplified by antiangiogenic drugs, creates new complexities in the assessment of response. The Quantitative Imaging Network addresses the need for imaging modalities which can accurately and reproducibly measure not just change in tumor size but changes in relevant metabolic parameters, modulation of relevant signaling pathways, drug delivery to tumor and differentiation of apoptotic cell death from other changes in tumor volume. This article provides an overview of the applications of quantitative imaging to phase 0 through phase 3 oncology trials. We describe the use of a range of quantitative imaging modalities in specific tumor types including malignant gliomas, lung cancer, head and neck cancer, lymphoma, breast cancer, prostate cancer and sarcoma. In the concluding section, we discuss potential constraints on clinical trials using quantitative imaging, including complexity of trial conduct, impact on subject recruitment, incremental costs and institutional barriers. Strategies for overcoming these constraints are presented.

    Original languageEnglish (US)
    Pages (from-to)1301-1312
    Number of pages12
    JournalMagnetic Resonance Imaging
    Volume30
    Issue number9
    DOIs
    StatePublished - Nov 2012

    Fingerprint

    Oncology
    Clinical Trials
    Head and Neck Neoplasms
    Imaging techniques
    Prostatic Neoplasms
    Tumors
    Breast Neoplasms
    Neoplasms
    Tumor Burden
    Glioma
    Sarcoma
    Pharmaceutical Preparations
    Positron-Emission Tomography
    Lymphoma
    Lung Neoplasms
    Cell Death
    Tomography
    Magnetic Resonance Imaging
    Costs and Cost Analysis
    Therapeutics

    Keywords

    • Cancer
    • Clinical trials
    • CT
    • MRI
    • PET
    • Quantitative imaging

    ASJC Scopus subject areas

    • Biophysics
    • Radiology Nuclear Medicine and imaging
    • Biomedical Engineering

    Cite this

    Kurland, B. F., Gerstner, E. R., Mountz, J. M., Schwartz, L. H., Ryan, C., Graham, M. M., ... Lieberman, F. S. (2012). Promise and pitfalls of quantitative imaging in oncology clinical trials. Magnetic Resonance Imaging, 30(9), 1301-1312. https://doi.org/10.1016/j.mri.2012.06.009

    Promise and pitfalls of quantitative imaging in oncology clinical trials. / Kurland, Brenda F.; Gerstner, Elizabeth R.; Mountz, James M.; Schwartz, Lawrence H.; Ryan, Christopher; Graham, Michael M.; Buatti, John M.; Fennessy, Fiona M.; Eikman, Edward A.; Kumar, Virendra; Forster, Kenneth M.; Wahl, Richard L.; Lieberman, Frank S.

    In: Magnetic Resonance Imaging, Vol. 30, No. 9, 11.2012, p. 1301-1312.

    Research output: Contribution to journalArticle

    Kurland, BF, Gerstner, ER, Mountz, JM, Schwartz, LH, Ryan, C, Graham, MM, Buatti, JM, Fennessy, FM, Eikman, EA, Kumar, V, Forster, KM, Wahl, RL & Lieberman, FS 2012, 'Promise and pitfalls of quantitative imaging in oncology clinical trials', Magnetic Resonance Imaging, vol. 30, no. 9, pp. 1301-1312. https://doi.org/10.1016/j.mri.2012.06.009
    Kurland, Brenda F. ; Gerstner, Elizabeth R. ; Mountz, James M. ; Schwartz, Lawrence H. ; Ryan, Christopher ; Graham, Michael M. ; Buatti, John M. ; Fennessy, Fiona M. ; Eikman, Edward A. ; Kumar, Virendra ; Forster, Kenneth M. ; Wahl, Richard L. ; Lieberman, Frank S. / Promise and pitfalls of quantitative imaging in oncology clinical trials. In: Magnetic Resonance Imaging. 2012 ; Vol. 30, No. 9. pp. 1301-1312.
    @article{33fcbb7e317744abab66d829ae108325,
    title = "Promise and pitfalls of quantitative imaging in oncology clinical trials",
    abstract = "Quantitative imaging using computed tomography, magnetic resonance imaging and positron emission tomography modalities will play an increasingly important role in the design of oncology trials addressing molecularly targeted, personalized therapies. The advent of molecularly targeted therapies, exemplified by antiangiogenic drugs, creates new complexities in the assessment of response. The Quantitative Imaging Network addresses the need for imaging modalities which can accurately and reproducibly measure not just change in tumor size but changes in relevant metabolic parameters, modulation of relevant signaling pathways, drug delivery to tumor and differentiation of apoptotic cell death from other changes in tumor volume. This article provides an overview of the applications of quantitative imaging to phase 0 through phase 3 oncology trials. We describe the use of a range of quantitative imaging modalities in specific tumor types including malignant gliomas, lung cancer, head and neck cancer, lymphoma, breast cancer, prostate cancer and sarcoma. In the concluding section, we discuss potential constraints on clinical trials using quantitative imaging, including complexity of trial conduct, impact on subject recruitment, incremental costs and institutional barriers. Strategies for overcoming these constraints are presented.",
    keywords = "Cancer, Clinical trials, CT, MRI, PET, Quantitative imaging",
    author = "Kurland, {Brenda F.} and Gerstner, {Elizabeth R.} and Mountz, {James M.} and Schwartz, {Lawrence H.} and Christopher Ryan and Graham, {Michael M.} and Buatti, {John M.} and Fennessy, {Fiona M.} and Eikman, {Edward A.} and Virendra Kumar and Forster, {Kenneth M.} and Wahl, {Richard L.} and Lieberman, {Frank S.}",
    year = "2012",
    month = "11",
    doi = "10.1016/j.mri.2012.06.009",
    language = "English (US)",
    volume = "30",
    pages = "1301--1312",
    journal = "Magnetic Resonance Imaging",
    issn = "0730-725X",
    publisher = "Elsevier Inc.",
    number = "9",

    }

    TY - JOUR

    T1 - Promise and pitfalls of quantitative imaging in oncology clinical trials

    AU - Kurland, Brenda F.

    AU - Gerstner, Elizabeth R.

    AU - Mountz, James M.

    AU - Schwartz, Lawrence H.

    AU - Ryan, Christopher

    AU - Graham, Michael M.

    AU - Buatti, John M.

    AU - Fennessy, Fiona M.

    AU - Eikman, Edward A.

    AU - Kumar, Virendra

    AU - Forster, Kenneth M.

    AU - Wahl, Richard L.

    AU - Lieberman, Frank S.

    PY - 2012/11

    Y1 - 2012/11

    N2 - Quantitative imaging using computed tomography, magnetic resonance imaging and positron emission tomography modalities will play an increasingly important role in the design of oncology trials addressing molecularly targeted, personalized therapies. The advent of molecularly targeted therapies, exemplified by antiangiogenic drugs, creates new complexities in the assessment of response. The Quantitative Imaging Network addresses the need for imaging modalities which can accurately and reproducibly measure not just change in tumor size but changes in relevant metabolic parameters, modulation of relevant signaling pathways, drug delivery to tumor and differentiation of apoptotic cell death from other changes in tumor volume. This article provides an overview of the applications of quantitative imaging to phase 0 through phase 3 oncology trials. We describe the use of a range of quantitative imaging modalities in specific tumor types including malignant gliomas, lung cancer, head and neck cancer, lymphoma, breast cancer, prostate cancer and sarcoma. In the concluding section, we discuss potential constraints on clinical trials using quantitative imaging, including complexity of trial conduct, impact on subject recruitment, incremental costs and institutional barriers. Strategies for overcoming these constraints are presented.

    AB - Quantitative imaging using computed tomography, magnetic resonance imaging and positron emission tomography modalities will play an increasingly important role in the design of oncology trials addressing molecularly targeted, personalized therapies. The advent of molecularly targeted therapies, exemplified by antiangiogenic drugs, creates new complexities in the assessment of response. The Quantitative Imaging Network addresses the need for imaging modalities which can accurately and reproducibly measure not just change in tumor size but changes in relevant metabolic parameters, modulation of relevant signaling pathways, drug delivery to tumor and differentiation of apoptotic cell death from other changes in tumor volume. This article provides an overview of the applications of quantitative imaging to phase 0 through phase 3 oncology trials. We describe the use of a range of quantitative imaging modalities in specific tumor types including malignant gliomas, lung cancer, head and neck cancer, lymphoma, breast cancer, prostate cancer and sarcoma. In the concluding section, we discuss potential constraints on clinical trials using quantitative imaging, including complexity of trial conduct, impact on subject recruitment, incremental costs and institutional barriers. Strategies for overcoming these constraints are presented.

    KW - Cancer

    KW - Clinical trials

    KW - CT

    KW - MRI

    KW - PET

    KW - Quantitative imaging

    UR - http://www.scopus.com/inward/record.url?scp=84867138623&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84867138623&partnerID=8YFLogxK

    U2 - 10.1016/j.mri.2012.06.009

    DO - 10.1016/j.mri.2012.06.009

    M3 - Article

    C2 - 22898682

    AN - SCOPUS:84867138623

    VL - 30

    SP - 1301

    EP - 1312

    JO - Magnetic Resonance Imaging

    JF - Magnetic Resonance Imaging

    SN - 0730-725X

    IS - 9

    ER -